title: Endoglin expression is associated with poor oncologic outcome in oral and oropharyngeal carcinoma.
abstract: CONCLUSIONS
  The present preliminary results suggest that endoglin (CD105)-assessed micro-vessel density (MVD) in primary oral and oropharyngeal squamous cell carcinomas (SCCs) may identify patients at risk of disease recurrence or poor oncological outcome after treatment.
  
  
  OBJECTIVE
  MVD is an independent prognostic indicator in several human malignancies. Endoglin antibodies have shown a greater specificity for tumour vasculature in comparison with pan-endothelial markers. The present explorative study evaluated endoglin expression and its prognostic role in oral and oropharyngeal SCCs.
  
  
  METHODS
  The study considered 13 consecutive cases of oral and oropharyngeal SCC with lymph node metastases (pN+) and 13 consecutive pN0 cases. CD105-assessed MVD was calculated at 400x magnification.
  
  
  RESULTS
  The mean MVDs were 3.6 and 3.1 in pN+ and pN0 groups, respectively (p>0.05). The mean CD105-assessed MVDs were 4.7 in the group with locoregional recurrence and 2.9 in the group without locoregional recurrence or post-treatment diagnosis of distant metastasis (p=0.01). The mean CD105-assessed MVD in primary oral and oropharyngeal SCCs with poor oncological outcome (recurrence of disease or occurrence of distant metastasis) was 4.3. The mean MVD in primary oral and oropharyngeal SCCs with good outcome was 2.9. Statistical analysis showed a significant difference between CD105-assessed MVD in poor and good outcome groups (p=0.02).
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, University of Padova, Italy. g_marioni@virgilio.it
authors.forename: Gino
authors.initials: G
authors.lastname: Marioni
authors.forename: Filippo
authors.initials: F
authors.lastname: Marino
authors.forename: Luciano
authors.initials: L
authors.lastname: Giacomelli
authors.forename: Claudia
authors.initials: C
authors.lastname: Staffieri
authors.forename: Maria Livia
authors.initials: ML
authors.lastname: Mariuzzi
authors.forename: Elena
authors.initials: E
authors.lastname: Violino
authors.forename: Cosimo
authors.initials: C
authors.lastname: De Filippis
mesh_terms: D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002294:Carcinoma, Squamous Cell / Q000098:blood supply / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D000071063:Endoglin; D004730:Endothelium, Vascular / Q000473:pathology; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000098:blood supply / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000473:pathology; D009959:Oropharyngeal Neoplasms / Q000098:blood supply / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000032:analysis*; D013223:Statistics as Topic; D015996:Survival Rate
chemical_list: D015703:Antigens, CD; D014408:Biomarkers, Tumor; C064206:ENG protein, human; D000071063:Endoglin; D011956:Receptors, Cell Surface